Similarly, the broad tyrosine kinase inhibitor nintedanib (anti-VEGFR, -FGFR, -PDGFR), developed as an angiogenesis inhibitor, increases responses to docetaxel in non–small cell lung cancer patients (47) and has also shown some efficacy in the treatment of idiopathic pulmonary fibrosis (48). Here, PDGFRB is linked to pulmonary fibrosis.